157 related articles for article (PubMed ID: 33867154)
21. Brigatinib: First Global Approval.
Markham A
Drugs; 2017 Jul; 77(10):1131-1135. PubMed ID: 28597393
[TBL] [Abstract][Full Text] [Related]
22. Brigatinib is a cost-effective treatment in first-line anaplastic lymphoma kinase mutation-positive (ALK + ) advanced non-small cell lung cancer (NSCLC) with brain metastases.
Giuliani J
J Oncol Pharm Pract; 2022 Apr; 28(3):691-694. PubMed ID: 34994227
[No Abstract] [Full Text] [Related]
23. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
Camidge DR; Kim DW; Tiseo M; Langer CJ; Ahn MJ; Shaw AT; Huber RM; Hochmair MJ; Lee DH; Bazhenova LA; Gold KA; Ou SI; West HL; Reichmann W; Haney J; Clackson T; Kerstein D; Gettinger SN
J Clin Oncol; 2018 Sep; 36(26):2693-2701. PubMed ID: 29768119
[TBL] [Abstract][Full Text] [Related]
24. Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient.
Hochmair M; Weinlinger C; Prosch H
Anticancer Drugs; 2019 Nov; 30(10):1058-1060. PubMed ID: 31033499
[TBL] [Abstract][Full Text] [Related]
25. Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease.
Doménech M; Jové M; Aso S; Marín M; Nadal E
Lung Cancer; 2018 May; 119():99-102. PubMed ID: 29656760
[TBL] [Abstract][Full Text] [Related]
26. Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution.
Hochmair M; Weinlinger C; Schwab S; Naber J; Setinek U; Krenbek D; Urban MH; Fabikan H; Watzka S; Koger R; Fazekas A; Bitterlich E; Valipour A; Burghuber OC
Anticancer Drugs; 2019 Aug; 30(7):e0787. PubMed ID: 31305295
[TBL] [Abstract][Full Text] [Related]
27. Brigatinib: Novel ALK Inhibitor for Non-Small-Cell Lung Cancer.
Spencer SA; Riley AC; Matthew A; Di Pasqua AJ
Ann Pharmacother; 2019 Jun; 53(6):621-626. PubMed ID: 30638036
[TBL] [Abstract][Full Text] [Related]
28. Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report.
Li S; Zhang P; Wang T; Wang J; Duan J
Thorac Cancer; 2021 Dec; 12(23):3273-3276. PubMed ID: 34647426
[TBL] [Abstract][Full Text] [Related]
29. High efficacy of brigatinib for brain metastases in ALK fusion gene-positive non-small cell lung cancer: A case series.
Morikawa K; Numata Y; Shinozaki Y; Kaneko S; Matsushima A; Nishida M; Kida H; Handa H; Nishine H; Mineshita M
Thorac Cancer; 2024 Feb; 15(6):496-499. PubMed ID: 38158887
[TBL] [Abstract][Full Text] [Related]
30. Brigatinib for
Ali R; Arshad J; Palacio S; Mudad R
Drug Des Devel Ther; 2019; 13():569-580. PubMed ID: 30804663
[TBL] [Abstract][Full Text] [Related]
31. Brigatinib effective in ALK-positive non-small-cell lung cancer.
Das M
Lancet Oncol; 2017 Jun; 18(6):e310. PubMed ID: 28506557
[No Abstract] [Full Text] [Related]
32. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
Popat S; Brustugun OT; Cadranel J; Felip E; Garassino MC; Griesinger F; Helland Å; Hochmair M; Pérol M; Bent-Ennakhil N; Kruhl C; Novello S
Lung Cancer; 2021 Jul; 157():9-16. PubMed ID: 34051652
[TBL] [Abstract][Full Text] [Related]
33. Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study.
Kawata AK; Lenderking WR; Eseyin OR; Kerstein D; Huang J; Huang H; Zhang P; Lin HM
J Med Econ; 2019 Sep; 22(9):924-935. PubMed ID: 31125274
[No Abstract] [Full Text] [Related]
34. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S; Anjum R; Squillace R; Nadworny S; Zhou T; Keats J; Ning Y; Wardwell SD; Miller D; Song Y; Eichinger L; Moran L; Huang WS; Liu S; Zou D; Wang Y; Mohemmad Q; Jang HG; Ye E; Narasimhan N; Wang F; Miret J; Zhu X; Clackson T; Dalgarno D; Shakespeare WC; Rivera VM
Clin Cancer Res; 2016 Nov; 22(22):5527-5538. PubMed ID: 27780853
[TBL] [Abstract][Full Text] [Related]
35. Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients.
Geraud A; Mezquita L; Bigot F; Caramella C; Planchard D; Le Pechoux C; Besse B
J Thorac Oncol; 2018 Nov; 13(11):e215-e217. PubMed ID: 29885478
[No Abstract] [Full Text] [Related]
36. Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis.
Gaye E; Geier M; Bore P; Guilloïque M; Lucia F; Quéré G; Gouva S; Robinet G; Descourt R
Lung Cancer; 2019 Jul; 133():1-3. PubMed ID: 31200813
[TBL] [Abstract][Full Text] [Related]
37. Early-Onset Pulmonary Events with Combined Brigatinib and Afatinib Treatment of L858/cisT790M/cisC797S NSCLC: A Case Report.
Lee BJ; Lim CK; Chang HT; Zhang JH
Am J Case Rep; 2022 Sep; 23():e937209. PubMed ID: 36146910
[TBL] [Abstract][Full Text] [Related]
38. Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.
Pellegrino B; Facchinetti F; Bordi P; Silva M; Gnetti L; Tiseo M
Clin Lung Cancer; 2018 Mar; 19(2):e151-e161. PubMed ID: 29174221
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC.
Gupta N; Reckamp KL; Camidge DR; Kleijn HJ; Ouerdani A; Bellanti F; Maringwa J; Hanley MJ; Wang S; Zhang P; Venkatakrishnan K
Clin Transl Sci; 2022 May; 15(5):1143-1154. PubMed ID: 35041775
[TBL] [Abstract][Full Text] [Related]
40. Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.
Tu J; Song LT; Liu RR; Zhai HL; Wang J; Zhang XY
J Cell Biochem; 2019 Jan; 120(1):562-574. PubMed ID: 30191596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
